BIOHEART
Shanghai Baixin'an Biotechnology Co., Ltd. is to develop independent innovative products in the future, continuously develop high-value minimally invasive therapeutic products, provide better medical products and technologies for medical workers and patients, and make the largest medical and health care business. s hard work.
BIOHEART
Industry:
Biotechnology Medical Medical Device
Founded:
2014-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.bio-heart.com
Total Employee:
11+
Status:
Active
Contact:
+021-68798511
Total Funding:
8.54 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apache Euro PHP Apache 2.4 Pound Sterling Japanese Yen OpenSSL
Similar Organizations
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
CuResponse
Curesponse is a medical company developing a three-dimensional tissue culture system for modeling cancer growth and drug response.
Sesen Bio, Inc.
Sesen Bio, Inc. is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Sinocelltech
Sinocelltech is a biotech company that develops and manufactures recombinant proteins, monoclonal antibodies, and vaccines.
Current Employees Featured
Founder
Investors List
BioVenture
BioVenture investment in Series B - Bioheart
CD Capital
CD Capital investment in Series B - Bioheart
Zhejiang Venture Capital
Zhejiang Venture Capital investment in Series B - Bioheart
Qianhai Fund of Funds
Qianhai Fund of Funds investment in Series B - Bioheart
CD Capital
CD Capital investment in Series B - Bioheart
